Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Laif® 900, BAY98-7108
Laif 900, BAY98-7108 · 1 trial · 1 indication
Definition: Increase of the Hamilton rating scale for depression (HAMD)-17 total score in Phase 2 by \> 5 points compared to Phase 2 baseline, if at the same time a total score of at least 12 is reached.
| Arm | Type | Description |
|---|---|---|
| Hypericum extract STW 3-VI (Laif® 900, BAY98-7108) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Laif® 900, BAY98-7108 | DRUG | 1 x daily, 1 tablet, 900 mg |
| Placebo | DRUG | 1 x daily, 1 tablet, 900 mg |
Inclusion Criteria: Study Phase 1: * Age 18-70 years * Diagnosis according to DSM-IV-TR: 296.32: Outpatients with a mediocre depressive episode requiring treatment for recurrent major depression * At least 5 of the following symptoms must persist for 2 weeks, with at least one of the main symptoms...
Laif 900 is being developed for the treatment of moderate depressive episodes, also described as major depression. It is a small molecule studied in adult outpatients aged 18 years and older. Development is at Phase 3, and the compound is also known as BAY98-7108.
Laif 900 is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor behind the clinical program evaluating the drug in moderate depressive episodes. The asset is also referred to as BAY98-7108 in company and trial documentation.
Laif 900 is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently listed as active. The program has enrolled 398 participants in total, and the drug remains investigational rather than approved.
Laif 900 has been studied in the Phase 3 trial NCT04315597, titled a study to learn about relapse prevention of Hypericum extract in outpatients suffering from moderate depressive episodes. The trial is completed, enrolled 398 participants, was randomized, double blind, and placebo controlled, and included adults 18 years and older.
Yes, Laif 900 and BAY98-7108 refer to the same investigational drug from Bayer AG. Laif 900 is the brand-style name, while BAY98-7108 is the company code used in development documentation. Both names point to the same Phase 3 asset for moderate depressive episodes.